Health Care & Life Sciences » Pharmaceuticals | InDex Pharmaceuticals Holding AB

InDex Pharmaceuticals Holding AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2014
2015
2016
2017
Sales/Revenue
45,160.00
376.00
176.00
113.00
Cost of Goods Sold (COGS) incl. D&A
57,346.00
29,850.00
39,934.00
73,428.00
Gross Income
12,186.00
29,474.00
39,758.00
73,315.00
EBIT
12,186.00
29,474.00
39,758.00
73,315.00
Non Operating Income/Expense
1.00
413.00
1,518.00
556.00
Pretax Income
10,395.00
29,881.00
41,275.00
72,759.00
Income Tax
4,475.00
-
-
-
Consolidated Net Income
14,870.00
29,881.00
41,275.00
72,759.00
Net Income
14,870.00
29,881.00
41,275.00
72,759.00
Net Income After Extraordinaries
14,870.00
29,881.00
41,275.00
72,759.00
Net Income Available to Common
14,870.00
29,881.00
41,275.00
72,759.00
EPS (Basic)
0.24
0.48
1.08
1.16
Basic Shares Outstanding
62,805.30
62,805.30
38,110.60
62,527.40
EPS (Diluted)
0.24
0.48
1.08
1.16
Diluted Shares Outstanding
62,805.30
62,805.30
38,110.60
62,527.40
EBITDA
12,075.00
29,379.00
39,691.00
73,304.00
Non-Operating Interest Income
1,792.00
6.00
1.00
-

About InDex Pharmaceuticals Holding AB

View Profile
Address
Tomtebodavägen 23 A
Stockholm AB 171 77
Sweden
Employees -
Website http://www.indexpharma.com
Updated 09/14/2018
InDex Pharmaceuticals Holding AB discovers and develops drugs for the treatment of diseases such as inflammation and cancer. It conducts research, technology development, and commercialization of scientific discoveries in the biomedical field. The firm also develops a platform of patent-protected substances, so-called deoxyribonucleic acid-based ImmunModulatory Sequences, with the potential to be used for the treatment of various immunological diseases.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.